As of 2025-06-29, the Intrinsic Value of GlaxoSmithKline Pharmaceuticals Ltd (GLAXO.NS) is 865.65 INR. This GLAXO.NS valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 3,439.60 INR, the upside of GlaxoSmithKline Pharmaceuticals Ltd is -74.80%.
The range of the Intrinsic Value is 742.35 - 1,058.45 INR
Based on its market price of 3,439.60 INR and our intrinsic valuation, GlaxoSmithKline Pharmaceuticals Ltd (GLAXO.NS) is overvalued by 74.80%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 742.35 - 1,058.45 | 865.65 | -74.8% |
| DCF (Growth 10y) | 899.66 - 1,248.55 | 1,037.22 | -69.8% |
| DCF (EBITDA 5y) | 1,699.58 - 2,132.95 | 1,898.16 | -44.8% |
| DCF (EBITDA 10y) | 1,663.63 - 2,184.59 | 1,898.46 | -44.8% |
| Fair Value | 1,368.84 - 1,368.84 | 1,368.84 | -60.20% |
| P/E | 1,868.20 - 2,180.41 | 1,985.85 | -42.3% |
| EV/EBITDA | 1,550.97 - 2,003.81 | 1,753.30 | -49.0% |
| EPV | 404.32 - 459.27 | 431.79 | -87.4% |
| DDM - Stable | 342.67 - 692.39 | 517.53 | -85.0% |
| DDM - Multi | 674.03 - 984.10 | 795.22 | -76.9% |
| Market Cap (mil) | 582,702.60 |
| Beta | 0.48 |
| Outstanding shares (mil) | 169.41 |
| Enterprise Value (mil) | 568,766.94 |
| Market risk premium | 8.31% |
| Cost of Equity | 13.15% |
| Cost of Debt | 7.64% |
| WACC | 13.15% |